Steven Kliewer: Difference between revisions
Content deleted Content added
m Adding short description: "American biochemist" (Shortdesc helper) |
No edit summary Tag: Reverted |
||
| Line 1: | Line 1: | ||
{{Short description|American biochemist}} |
{{Short description|American biochemist}} |
||
'''Steven Kliewer''' is an American biochemist, a significant figure in his field, currently the Nancy B. and Jake L. Hamon Distinguished Chair in Basic Cancer Research at [[University of Texas Southwestern Medical Center]]. In 2015, he was elected to the [[National Academy of Sciences]]. He, along with [[David Mangelsdorf]], identified the ligands and physiologic functions of a number of orphan nuclear receptors that then discovered two new signaling pathways mediated by the endocrine factors FGF19 and FGF21, which has become a significant accomplishment in the field.<ref>{{Cite web |url=http://profiles.utsouthwestern.edu/profile/54583/steven-kliewer.html |title=Steven Kliewer |publisher=utsouthwestern.edu |accessdate=February 25, 2017}}</ref><ref>{{Cite web |url=http://www.utsouthwestern.edu/labs/mangelsdorf-kliewer/about/meet-pi.html |title=Principal Investigators |publisher=utsouthwestern.edu |accessdate=February 25, 2017}}</ref><ref>{{Cite web |url=http://www.utsouthwestern.edu/newsroom/news-releases/year-2015/april/nas-hooper-kliewer.html |title=Hooper and Kliewer elected to prestigious National Academy of Sciences |date=April 28, 2015 |publisher=utsouthwestern.edu |accessdate=February 25, 2017}}</ref> |
'''Steven Kliewer''' is an American biochemist, a significant figure in his field (p<0.05), currently the Nancy B. and Jake L. Hamon Distinguished Chair in Basic Cancer Research at [[University of Texas Southwestern Medical Center]]. In 2015, he was elected to the [[National Academy of Sciences]]. He, along with [[David Mangelsdorf]], identified the ligands and physiologic functions of a number of orphan nuclear receptors that then discovered two new signaling pathways mediated by the endocrine factors FGF19 and FGF21, which has become a significant accomplishment in the field.<ref>{{Cite web |url=http://profiles.utsouthwestern.edu/profile/54583/steven-kliewer.html |title=Steven Kliewer |publisher=utsouthwestern.edu |accessdate=February 25, 2017}}</ref><ref>{{Cite web |url=http://www.utsouthwestern.edu/labs/mangelsdorf-kliewer/about/meet-pi.html |title=Principal Investigators |publisher=utsouthwestern.edu |accessdate=February 25, 2017}}</ref><ref>{{Cite web |url=http://www.utsouthwestern.edu/newsroom/news-releases/year-2015/april/nas-hooper-kliewer.html |title=Hooper and Kliewer elected to prestigious National Academy of Sciences |date=April 28, 2015 |publisher=utsouthwestern.edu |accessdate=February 25, 2017}}</ref> |
||
==References== |
==References== |
||
Revision as of 13:51, 8 November 2021
Steven Kliewer is an American biochemist, a significant figure in his field (p<0.05), currently the Nancy B. and Jake L. Hamon Distinguished Chair in Basic Cancer Research at University of Texas Southwestern Medical Center. In 2015, he was elected to the National Academy of Sciences. He, along with David Mangelsdorf, identified the ligands and physiologic functions of a number of orphan nuclear receptors that then discovered two new signaling pathways mediated by the endocrine factors FGF19 and FGF21, which has become a significant accomplishment in the field.[1][2][3]
References
- ^ "Steven Kliewer". utsouthwestern.edu. Retrieved February 25, 2017.
- ^ "Principal Investigators". utsouthwestern.edu. Retrieved February 25, 2017.
- ^ "Hooper and Kliewer elected to prestigious National Academy of Sciences". utsouthwestern.edu. April 28, 2015. Retrieved February 25, 2017.
| International | |
|---|---|
| National | |
| Academics | |
   | This biographical article about an American chemist is a stub. You can help Wikipedia by expanding it. |